ENSYSCE BIOSCIENCES INC (ENSC)
US2936024056 - Common Stock
Taking everything into account, ENSC scores 1 out of 10 in our fundamental rating. ENSC was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of ENSC have multiple concerns. While showing a medium growth rate, ENSC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ENSC has reported negative net income.
In the past year ENSC has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ENSC reported negative net income in multiple years.
In the past 5 years ENSC always reported negative operating cash flow.
1.2 Ratios
ENSC has a worse Return On Assets (-392.69%) than 96.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -392.69% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ENSC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ENSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ENSC has been increased compared to 1 year ago.
ENSC has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ENSC has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -75.17, we must say that ENSC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -75.17, ENSC is not doing good in the industry: 95.38% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -75.17 |
ROIC/WACCN/A
WACC4.73%
2.3 Liquidity
A Current Ratio of 0.69 indicates that ENSC may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.69, ENSC is doing worse than 94.01% of the companies in the same industry.
ENSC has a Quick Ratio of 0.69. This is a bad value and indicates that ENSC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.69, ENSC is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.69 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 94.65% over the past year.
Looking at the last year, ENSC shows a very negative growth in Revenue. The Revenue has decreased by -11.31% in the last year.
EPS 1Y (TTM)94.65%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q92.49%
Revenue 1Y (TTM)-11.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-63.98%
3.2 Future
Based on estimates for the next years, ENSC will show a very strong growth in Earnings Per Share. The EPS will grow by 74.78% on average per year.
Based on estimates for the next years, ENSC will show a very strong growth in Revenue. The Revenue will grow by 157.05% on average per year.
EPS Next Y41.78%
EPS Next 2Y24.52%
EPS Next 3Y74.78%
EPS Next 5YN/A
Revenue Next Year-17.5%
Revenue Next 2Y160.83%
Revenue Next 3Y210.35%
Revenue Next 5Y157.05%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENSC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ENSC's earnings are expected to grow with 74.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.52%
EPS Next 3Y74.78%
5. Dividend
5.1 Amount
ENSC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENSYSCE BIOSCIENCES INC
NASDAQ:ENSC (4/26/2024, 7:00:02 PM)
0.5842
+0.04 (+6.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.84M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -392.69% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.69 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)94.65%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y41.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-11.31%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y